X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA BIOCON LTD AJANTA PHARMA/
BIOCON LTD
 
P/E (TTM) x 20.7 36.7 56.3% View Chart
P/BV x 8.9 4.9 183.0% View Chart
Dividend Yield % 0.7 1.5 44.3%  

Financials

 AJANTA PHARMA   BIOCON LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
BIOCON LTD
Mar-16
AJANTA PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,720496 347.0%   
Low Rs1,103397 278.2%   
Sales per share (Unadj.) Rs194.6174.3 111.7%  
Earnings per share (Unadj.) Rs45.244.8 100.9%  
Cash flow per share (Unadj.) Rs50.356.9 88.4%  
Dividends per share (Unadj.) Rs8.005.00 160.0%  
Dividend yield (eoy) %0.61.1 50.6%  
Book value per share (Unadj.) Rs132.0202.8 65.1%  
Shares outstanding (eoy) m88.77200.00 44.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.32.6 283.3%   
Avg P/E ratio x31.210.0 313.5%  
P/CF ratio (eoy) x28.17.8 358.1%  
Price / Book Value ratio x10.72.2 485.9%  
Dividend payout %17.711.2 158.5%   
Avg Mkt Cap Rs m125,29989,220 140.4%   
No. of employees `000NA4.4 0.0%   
Total wages/salary Rs m2,5706,363 40.4%   
Avg. sales/employee Rs ThNM7,894.5-  
Avg. wages/employee Rs ThNM1,441.2-  
Avg. net profit/employee Rs ThNM2,029.7-  
INCOME DATA
Net Sales Rs m17,27534,854 49.6%  
Other income Rs m166845 19.7%   
Total revenues Rs m17,44235,699 48.9%   
Gross profit Rs m5,8078,200 70.8%  
Depreciation Rs m4512,423 18.6%   
Interest Rs m49102 47.9%   
Profit before tax Rs m5,4746,520 84.0%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m05,754 0.0%   
Tax Rs m1,4602,569 56.8%   
Profit after tax Rs m4,0148,961 44.8%  
Gross profit margin %33.623.5 142.9%  
Effective tax rate %26.739.4 67.7%   
Net profit margin %23.225.7 90.4%  
BALANCE SHEET DATA
Current assets Rs m7,63939,932 19.1%   
Current liabilities Rs m2,71516,276 16.7%   
Net working cap to sales %28.567.9 42.0%  
Current ratio x2.82.5 114.7%  
Inventory Days Days4354 80.7%  
Debtors Days Days7986 91.3%  
Net fixed assets Rs m6,91439,101 17.7%   
Share capital Rs m1771,000 17.7%   
"Free" reserves Rs m11,44238,591 29.6%   
Net worth Rs m11,72140,556 28.9%   
Long term debt Rs m14920,724 0.7%   
Total assets Rs m14,81484,816 17.5%  
Interest coverage x112.964.9 174.0%   
Debt to equity ratio x00.5 2.5%  
Sales to assets ratio x1.20.4 283.8%   
Return on assets %27.410.7 256.7%  
Return on equity %34.222.1 155.0%  
Return on capital %46.519.0 245.1%  
Exports to sales %55.130.7 179.4%   
Imports to sales %6.020.4 29.5%   
Exports (fob) Rs m9,52710,717 88.9%   
Imports (cif) Rs m1,0387,105 14.6%   
Fx inflow Rs m10,42211,789 88.4%   
Fx outflow Rs m1,6788,393 20.0%   
Net fx Rs m8,7443,396 257.5%   
CASH FLOW
From Operations Rs m3,2645,264 62.0%  
From Investments Rs m-2,093-9,540 21.9%  
From Financial Activity Rs m-1,18610,867 -10.9%  
Net Cashflow Rs m-156,591 -0.2%  

Share Holding

Indian Promoters % 73.8 40.4 182.7%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 1.6 8.4 18.5%  
FIIs % 7.6 10.7 71.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 19.9 85.4%  
Shareholders   20,968 109,995 19.1%  
Pledged promoter(s) holding % 4.4 0.0 10,975.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   STRIDES SHASUN LTD  CADILA HEALTHCARE  SUVEN LIFE  DR. DATSONS LABS  WOCKHARDT LTD.  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 23, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - STRIDES SHASUN LTD COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS